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BACKGROUND: Early detection of adverse effects of novel therapies and 
understanding of their mechanisms could improve the safety and efficiency 
of drug development. We have retrospectively applied large-scale proteomics 
to blood samples from ILLUMINATE (Investigation of Lipid Level Management 
to Understand its Impact in Atherosclerotic Events), a trial of torcetrapib (a 
cholesterol ester transfer protein inhibitor), that involved 15 067 participants at 
high cardiovascular risk. ILLUMINATE was terminated at a median of 550 days 
because of significant absolute increases of 1.2% in cardiovascular events and 
0.4% in mortality with torcetrapib. The aims of our analysis were to determine 
whether a proteomic analysis might reveal biological mechanisms responsible 
for these harmful effects and whether harmful effects of torcetrapib could have 
been detected early in the ILLUMINATE trial with proteomics.
METHODS: A nested case-control analysis of paired plasma samples at baseline 
and at 3 months was performed in 249 participants assigned to torcetrapib plus 
atorvastatin and 223 participants assigned to atorvastatin only. Within each 
treatment arm, cases with events were matched to controls 1:1. Main outcomes 
were a survey of 1129 proteins for discovery of biological pathways altered by 
torcetrapib and a 9-protein risk score validated to predict myocardial infarction, 
stroke, heart failure, or death.
RESULTS: Plasma concentrations of 200 proteins changed significantly with 
torcetrapib. Their pathway analysis revealed unexpected and widespread changes 
in immune and inflammatory functions, as well as changes in endocrine systems, 
including in aldosterone function and glycemic control. At baseline, 9-protein 
risk scores were similar in the 2 treatment arms and higher in participants with 
subsequent events. At 3 months, the absolute 9-protein derived risk increased in 
the torcetrapib plus atorvastatin arm compared with the atorvastatin-only arm by 
1.08% (P=0.0004). Thirty-seven proteins changed in the direction of increased 
risk of 49 proteins previously associated with cardiovascular and mortality risk.
CONCLUSIONS: Heretofore unknown effects of torcetrapib were revealed 
in immune and inflammatory functions. A protein-based risk score predicted 
harm from torcetrapib within just 3 months. A protein-based risk assessment 
embedded within a large proteomic survey may prove to be useful in the 
evaluation of therapies to prevent harm to patients.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT00134264.
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In 2006, the results of the 15 067–patient ILLUMI-NATE trial (Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events)1 
were described as a “nightmare created by unintended 
pharmacological effects” of torcetrapib.2 Torcetrapib, a 
cholesteryl ester transfer protein inhibitor, given along-
side atorvastatin, raised high-density lipoprotein (HDL) 
cholesterol by a remarkable 72% and reduced low-
density lipoprotein (LDL) cholesterol by 25%. Despite 
these favorable changes in lipid profile, the trial was 
terminated after a median follow-up of 550 days be-
cause of significant absolute increases of 1.2% in car-
diovascular events and 0.4% in all-cause deaths in the 
torcetrapib plus atorvastatin arm compared with the 
atorvastatin-only arm.1 Aside from the harm to patients 
and the reported $1 billion cost of the failed torcetrapib 
development program,3 the misleading results from the 
previously trusted cardiovascular risk biomarkers LDL 
and HDL cholesterol have led to a view that these (and 
possibly other) biomarkers are not reliable surrogates 
for meaningful clinical outcomes.4,5 The consequences 
of this view are clinical drug development programs 
that are potentially harmful to patients, slow to com-
plete, and expensive. Indeed, the absence of reliable 
biomarkers to predict adverse drug effects in a timely 
manner and before harm to study participants accrues 
is currently regarded by the US Food and Drug Admin-
istration as a key obstacle to the pace of innovation in 
drug development across all diseases.6
Proteins are key regulators of biological processes 
and relate to the risk of diseases and their clinical out-
comes.7,8 The field of proteomics has matured over the 
past 20 years, and it is now poised to have a transfor-
mative impact on cardiovascular health and disease.9 
Technologies have been developed that can readily 
measure the levels of hundreds or even thousands of 
proteins in a small sample of blood.8,9 The objectives of 
this study were to use one such technology, modified 
aptamers,8,10–13 to measure plasma proteins in a nested 
case-control subset of patients from ILLUMINATE to de-
termine whether mechanistic insights into the harmful 
effects of torcetrapib could be discerned from an analy-
sis of 1129 plasma proteins with the tools of pathway 
analysis and to determine whether a previously validat-
ed 9-protein cardiovascular risk score8 could have de-
tected changes in cardiovascular and all-cause mortality 
risk over the first 3 months of assigned treatment with 
torcetrapib plus atorvastatin compared with atorvas-
tatin only.
METHODS
Study Population
ILLUMINATE was a prospective, multicenter, placebo-con-
trolled trial that randomized a total of 15 067 patients between 
August 23, 2004, and December 28, 2005.1 Men and women 
between the ages of 45 and 75 years were eligible to partici-
pate if they had a history of cardiovascular disease (myocardial 
infarction, stroke, acute coronary syndrome, unstable angina, 
peripheral vascular disease, and cardiac revascularization) or 
type 2 diabetes mellitus without overt cardiovascular disease. 
During a run-in period of 4 to 10 weeks, patients underwent 
lifestyle counseling and uptitration of atorvastatin, as needed, 
at 2-week intervals to achieve an LDL cholesterol level <100 
mg/dL. The trial was terminated prematurely on December 2, 
2006, because of significant absolute increases of 1.2% in 
cardiovascular events and 0.4% in mortality in patients receiv-
ing torcetrapib, with a median follow-up of 550 days and the 
longest follow-up of 880 days.1 An institutional review board 
at each ILLUMINATE center approved the study protocol, and 
patients provided written informed consent.1
Plasma Samples and Study Design
Plasma (EDTA) samples from the study participants were bio-
banked by the ILLUMINATE study sponsor (Pfizer Inc.). We 
used a nested case-control design14 to maximize the power to 
detect an effect by including all the participants with outcome 
events and available plasma samples. Paired plasma samples 
obtained at baseline and at 3 months from a total of 494 
Clinical Perspective
What Is New?
• Early detection of harmful effects of novel drug 
treatments and their mechanistic understanding 
could improve the safety of drug development.
• ILLUMINATE (Investigation of Lipid Level Manage-
ment to Understand its Impact in Atherosclerotic 
Events) was a trial of torcetrapib, a cholesterol ester 
transfer protein inhibitor, which raised high-density 
lipoprotein cholesterol and lowered low-density 
lipoprotein cholesterol. The trial was terminated 
because of increases in cardiovascular events and 
mortality.
• In a retrospective analysis of baseline and on-
treatment blood samples from ILLUMINATE, a 
large-scale proteomic analysis detected harm from 
torcetrapib at 3 months of treatment, before it 
became apparent clinically.
• Proteomic analysis revealed unexpected alterations 
in inflammation and immunity by torcetrapib and 
explained the previously reported activation of 
aldosterone.
What Are the Clinical Implications?
• A longitudinal survey of the proteome in blood 
samples can provide an early warning of unex-
pected harm from drug therapies and inform 
responsible mechanisms.
• Proteomics, a tool of precision medicine, may prove 
to be useful in improving the safety and efficiency 
of drug development.
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study participants were used to determine within-participant 
changes in plasma proteins during the first 3 months of ran-
domized treatment. All individuals selected as cases had a first 
event after the 3-month sample. Cases in this analysis were 
selected with the same definition of events used previously 
to derive and validate the 9-protein risk model (myocardial 
infarction, stroke/transient ischemic attack, hospitalization for 
heart failure, or all-cause death).8 Although not identical to 
the primary outcome of ILLUMINATE, each of the end points 
reported in the present analysis was adjudicated by a com-
mittee of ILLUMINATE as a primary or a secondary end-point 
of the trial.1 For each case, a matched control participant was 
selected within each treatment arm on the basis of the fol-
lowing baseline characteristics: atorvastatin dose (after the 
run-in uptitration period), presence of known coronary heart 
disease, diabetes status, age, sex, and censoring time. The 
baseline plasma samples were obtained before the participant 
was assigned treatment, after the run-in atorvastatin uptitra-
tion. The study flowchart is shown in Figure 1.
Quantification of Proteins in Human 
Plasma
In total, 988 plasma samples were analyzed by a modified 
aptamer assay.8 In brief, each of the 1129 individual proteins 
measured has its binding reagent made of chemically modi-
fied DNA, referred to as a modified aptamer. The assay ver-
sion was nearly identical to that described previously to derive 
a 9-protein cardiovascular risk score.8 Each sample of plasma 
was incubated with the mixture of modified aptamers to gen-
erate modified aptamer-protein complexes under equilibrium 
conditions. Unbound modified aptamers and unbound or 
nonspecifically bound proteins were eliminated by 2 bead-
based immobilization steps. After elution of the modified 
aptamers from the target protein, the fluorescently labeled 
modified aptamers were directly quantified on a hybridiza-
tion array (Agilent Technologies). Calibrators were included 
so that the degree of fluorescence was a consistent reflection 
of protein concentration. The median intra-assay, interassay, 
and total coefficients of variation for the 1129 proteins are all 
<4%. The distribution of coefficients of variation across the 
1129 proteins measured and coefficients of variation for each 
of the proteins within the 9-protein prognostic model8 are 
provided in Table I in the online-only Data Supplement. All of 
the 1129 protein targets are above the limit of detection as 
defined by the Clinical and Laboratory Standards Institute.15 
Of the 1129 proteins measured, 143 did not pass the interrun 
calibration quality control metrics in at least 1 of the thirteen 
96-well plates that were run and were thus excluded from 
further analysis (detailed information on exclusion of proteins 
is provided in Method I in the online-only Data Supplement). 
One sample of the 988 samples was not analyzed because 
of an error. Twenty-two samples did not pass the intrarun 
normalization quality control metrics and were excluded from 
analysis. In 2 samples, 10% of the protein measurements 
exceeded an outlier threshold defined as the median protein 
signal level±6 median absolute deviations and 5 times higher 
or lower than the median protein signal level. A further 19 
samples were removed from the analysis because their pair 
was not run, did not pass the quality control threshold, or 
exceeded the aforementioned outlier threshold. Overall, the 
exclusions from the protein assay and sample quality control 
metrics resulted in an assessment of 986 of the 1129 assayed 
proteins, 249 pairs of samples in the torcetrapib plus atorv-
astatin arm, and 223 pairs in the atorvastatin-only arm. The 
flow diagram is shown in Figure 1.
Statistical Methods
All samples were placed randomly on 96-well plates, run in a 
single batch, and normalized against protein calibrator sam-
ples included on each plate.8,11 Assay personnel were unaware 
of the treatment or the clinical outcome. Because the assay 
version was slightly more recent compared with that used to 
derive and validate the 9-protein model,8 60 bridging samples 
from the earlier analyses were used as protein standards to 
align the fluorescence readouts of the same proteins in the 
same samples across the different assay versions (Method II in 
the online-only Data Supplement).
For study objective 1, to discern the biological mechanisms 
of torcetrapib by assessing treatment-associated changes in 
plasma protein concentrations and organizing differentially 
expressed proteins according to biological pathways, dif-
ferences between the baseline and 3-month samples were 
expressed as log2 ratios for each of the 986 proteins mea-
sured that passed quality control. Significance values were 
calculated within each treatment arm with the Wilcoxon 
signed-rank test for paired comparisons corrected for a false 
discovery rate in 986 measurements and across treatment 
arms with the Wilcoxon signed-rank test for unpaired com-
parisons. Proteins with a false discovery rate–adjusted value 
of P<0.05 were considered statistically significant for inclu-
sion in the pathway analysis.
Ingenuity Pathway Analysis (IPA) was used to cluster dif-
ferentially expressed proteins at 3 months compared with 
Figure 1. Flowchart of samples, study participants, and 
analytic processes for the evaluation of torcetrapib.
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baseline into pathways and functional groups in the torce-
trapib plus atorvastatin treatment arm (IPA content version 
28820210, release date September 24, 2016, Ingenuity 
Systems Inc, Redwood City, CA; www.ingenuity.com). A path-
way analysis was not performed within the atorvastatin-only 
treatment arm because only a few proteins changed over 3 
months. For those modified aptamers that had multiple 
Uniprot identifications associated with 1 result, only the first 
listed Uniprot identification was used in the pathway analy-
sis. The Fisher right-tailed exact test was used to calculate a 
P value to determine the probability that the association of 
the differently expressed proteins in the measured data set, 
and the pathway is explained by chance alone. Of the 986 
proteins measured, 980 were recognized by IPA and used 
as the background reference. The pathway analysis results 
obtained by IPA, a commercial system, were confirmed by 2 
open-source pathway analysis systems, Reactome Pathway 
Database (http://reactome.org/) and Database for Annotation, 
Visualization and Integrated Discovery (DAVID) Bioinformatics 
resource (https://david.ncifcrf.gov/).
For study objective 2, to determine whether a previously 
validated 9-protein cardiovascular risk score could detect 
changes in risk over the first 3 months of assigned treatment 
with torcetrapib plus atorvastatin compared with atorvastatin 
only, the 9-protein risk score8 was calculated without recali-
bration to this study population. This 9-protein risk score was 
previously constructed by a rigorous bioinformatics process, 
starting from a total of 1130 plasma proteins.8 The model 
consists of the following 9 proteins (in rank order of their 
contribution to risk calculation): ANGPT2 (angiopoietin-2), 
GDF11/8 (growth differentiation factor 11/8), C7 (comple-
ment 7), SERPINF2 (α2-antiplasmin), CCL18 (chemokine [C-C 
motif] ligand 18), ANGPTL4 (angiopoietin-related protein 4), 
SERPINA3 (α1-antichymotrypsin complex), MMP12 (matrix 
metalloproteinase-12), and TNNI3 (troponin I).8 The prognos-
tic risk score is as follows:
risk score = − −
( )− 1
4
0 85.e e
Log PI
where the prognostic index (PI) combines the measure-
ments of the 9 proteins as follows:
PI ANGPT GDF C
SER
. . . / .
.
= − × + × − ×
+ ×
16 61 1 55 2 1 22 8 11 2 12 7
2 64 PINF CCL ANGPTL
SERPINA M
2 0 57 18 1 02 4
1 43 3 0 72
. .
. .
− × − ×
− × − × MP TNNI12 0 59 3. .− ×
The published risk score allows the calculation of prob-
abilities of events for any specified time horizon.8 For this 
application, an output of 550 days, the median duration of 
treatment for patients in ILLUMINATE,1 was selected so that 
the change in observed event rate in ILLUMINATE could be 
compared with the prediction of the 9-protein risk model.
For study objective 2, the analysis combined all partici-
pants with or without events within each of the 2 treatment 
arms. Changes in the 9-protein risk score between base-
line and 3 months were compared within each treatment 
arm with the paired Wilcoxon signed-rank test for paired 
comparisons. Changes in risk score in cases compared with 
controls within each treatment arm were also evaluated 
with the unpaired Wilcoxon rank-sum test. P values were 
not corrected for multiple comparisons. The Ansari-Bradley 
test16 was applied to discern whether torcetrapib-associated 
changes in the 9-protein risk score represented a single dis-
tribution and thus whether torcetrapib affected all individu-
als exposed.
Although most participants in the ILLUMINATE trial had 
known coronary heart disease and therefore matched the 
population on which the 9-protein model was derived, the 
study protocol also allowed enrollment of diabetics without 
known coronary heart disease, who represented 19% of the 
ILLUMINATE study population.1 Because no differences in distri-
butions of protein-based risk scores could be discerned between 
participants with coronary heart disease and the larger group 
of participants that also included diabetics without coronary 
heart disease (Figure I in the online-only Data Supplement), it 
was the larger group that was used in the analyses.
For comparative purposes, to clarify how reported torce-
trapib-associated increases in blood pressure in ILLUMINATE1 
balance out against improvements in HDL and LDL cholesterol 
levels for cardiovascular risk prediction, the Framingham sec-
ondary event risk prediction score was also calculated for the 
identical time horizon.17 This Framingham risk score is appli-
cable to patients with established cardiovascular disease such 
as those enrolled in the ILLUMINATE trial.17
All pathway analyses were performed at the University 
of California, San Francisco (by A.C.M. and P.G.). All other 
statistical analyses were performed initially at SomaLogic, 
Inc., (by S.J.W.) and replicated at University of California, San 
Francisco (by M.R.S.).
All statistical computing was performed with the R 
Language for Statistical Computing, version 3.3.1 at 
SomaLogic, Inc., and version 3.2.1 at the University of 
California, San Francisco.
RESULTS
Study Population Characteristics
The baseline characteristics of the study population af-
ter the atorvastatin uptitration run-in period are shown 
in Table 1. The 2 treatment arms were well matched. 
Within each arm, patients with outcome events (cases) 
were more likely to have lower estimated glomerular 
filtration rates and higher diastolic blood pressure than 
patients without events (controls). Compared with the 
entire ILLUMINATE study population,1 the participants 
in this analysis were older and more likely to be male 
and diabetic (data not shown). These differences are 
expected because they reflect the nested case-control 
study design with half of the participants experiencing 
outcomes events (cases) to which the control partici-
pants were matched for high-risk cardiovascular char-
acteristics, particularly age, sex, and diabetes status.
Mechanistic Insights Into the Effects on 
Torcetrapib Based on a Proteomic Survey 
and Pathway Analysis
In the torcetrapib plus atorvastatin arm, of the 986 pro-
teins measured, 200 proteins changed significantly in a 
univariate analysis at a false discovery rate of 5% (Table 
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II in the online-only Data Supplement). Of the 986 pro-
teins entered into the IPA, Uniprot identification names 
of 980 were recognized by IPA and used as the total 
number of background proteins. A pathway analysis of 
the 200 proteins affected by torcetrapib showed signifi-
cant enrichment for proteins involved in inflammation 
and immunity (Table 2). Specifically, among the top 10 
IPA canonical pathways (canonical pathways are well-
characterized metabolic and cell signaling pathways), 
8 are involved in inflammation and immunity (Table 2: 
B-cell receptor signaling, PPARα/RXRα [peroxisome 
proliferator-activated receptor-α/retinoid X receptor-α] 
activation, RAR [retinoic acid receptor] activation, role 
of NFAT [nuclear factor of activated T cells] in regula-
tion of the immune response, PI3K [phosphoinositide 
3-kinase] signaling in B lymphocytes, T-cell receptor sig-
naling, sphingosine-1-phosphate signaling, and trigger-
ing receptor expressed on myeloid cells 1 signaling). All 
the proteins contained within each of these top 10 IPA 
canonical pathways and those affected by torcetrapib 
are shown in Figures II through XI in the online-only 
Data Supplement. In addition, on the basis of IPA, a 
total of 19 proteins altered by torcetrapib are associ-
ated with endocrine system development and function, 
8 of which pertain to aldosterone synthesis or function, 
9 to insulin sensitivity (ie, glycemic control), and 2 to 
pancreatic β-cell function (ie, glycemic control; Table 3 
and Figures 2 and 3).
To validate our results derived from IPA, we analyzed 
the 200 proteins changed by torcetrapib using 2 addi-
tional pathway analysis resources. Table III in the online-
only Data Supplement shows the top 10 pathways iden-
tified by Reactome, and Table IV in the online-only Data 
Table 1. Baseline Characteristics of the Case-Control Study Population
Torcetrapib Plus Atorvastatin Atorvastatin Only
All Without Events With Events All Without Events With Events
Participant, n 249 127 122 223 109 114
Age, y 64.3 (7.7) 64.2 (7.6) 64.3 (7.8) 62.9 (7) 62.6 (7) 63.2 (7)
Male, % 82.3 82.3 82.0 79.8 79.8 79.8
White, % 96.8 97.6 95.9 90.6 88.1 92.3
Diabetes mellitus, % 56.2 55.1 57.4 59.6 59.6 59.6
Current smoker, % 12.0 7.1 17.2* 11.7 9.2 14.0
Time to event, d NA NA 325.9 (206.3) NA NA 340.6 (193.7)
BMI, kg/m2 30.3 (5.5) 30.3 (5.3) 30.3 (5.8) 30.6 (5.8) 30.1 (4.7) 31.1 (6.6)
LDL-C, mg/dL 77.6 (20.9) 76 (19.4) 80 (22.4) 78 (20.1) 77.1 (19.4) 78.9 (20.8)
HDL-C, mg/dL 48.2 (11.6) 47.7 (11.3) 48.6 (11.9) 48.4 (12.9) 50.3 (12.6) 46.6 (12.9)‡
Total cholesterol, mg/dL 154.2 (27.7) 152.1 (25.6) 156.4 (29.6) 157.7 (23.8) 157.2 (24.7) 158 (23.1)
Triglycerides, mg/dL 144 (78.7) 143.3 (71.1) 144.8 (86.1) 158.1 (85.1) 150.9 (74.6) 165 (93.9)
eGFR, mL/min 73.7 (17.1) 77.4 (15.5) 69.9 (17.9)‡ 75.7 (16.7) 79.4 (15) 72.1 (17.4)‡
Creatinine, mg/dL 1 (0.25) 1 (0.22) 1.1 (0.27)‡ 1 (0.24) 0.98 (0.2) 1.1 (0.27)‡
Systolic blood pressure, mm Hg 123.3 (11.9) 123.6 (10.6) 123 (13.2) 125.7 (11.6) 126.1 (10.7) 125.2 (12.4)
Diastolic blood pressure, mm Hg 71.7 (8.7) 73.1 (8.2) 70.3 (9)† 72.7 (8.7) 73.9 (8.4) 73.1 (8.9)†
Continuous values are summarized with mean (SD). 
BMI indicates body mass index; eGFR, estimated glomerular filtration rate calculated with Chronic Kidney Disease Epidemiology Collaboration 201218; HDL-C, 
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and NA, not applicable.
*Significant difference between events and no events. 
†P<0.05.
‡P<0.01.
Table 2. Top 10 IPA Canonical Pathways of the 200 
Proteins Significantly Altered by Torcetrapib
IPA Canonical Pathways P Value Ratio*
B-cell receptor signaling† 0.001 0.409 (18/44)
Calcium signaling 0.008 0.5 (8/16)
PPARα/RXRα activation† 0.010 0.378 (14/37)
RAR activation† 0.014 0.387 (12/31)
Role of NFAT in regulation of the  
immune response†
0.017 0.393 (11/28)
PI3K signaling in B lymphocytes† 0.022 0.379 (11/29)
T-cell receptor signaling† 0.022 0.379 (11/29)
Sphingosine-1-phosphate signaling† 0.022 0.409 (9/22)
PI3K/AKT signaling 0.022 0.409 (9/22)
TREM1 signaling† 0.028 0.421 (8/19)
AKT indicates protein kinase B; IPA, Ingenuity Pathway Analysis; NFAT, nuclear 
factor of activated T cells; PI3K, phosphoinositide 3-kinase; PPARα/RXRα, 
peroxisome proliferator-activated receptor-α/retinoid X receptor-α; RAR, retinoic 
acid receptor; and TREM1, triggering receptor expressed on myeloid cells 1. 
*The ratio indicates the number of significant proteins that map to the 
canonical pathway divided by the total number of proteins measured in our 
study that map to the same pathway. 
†Pathways identified by IPA as involved in inflammation or immunity.
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Supplement shows the top 20 KEGG and BioCarta path-
ways identified by DAVID. Notably, similar to our results 
from IPA, we found significant enrichment in pathways 
involving inflammatory and immune functions.
There were 18 proteins that changed significantly 
in the atorvastatin-only arm (Table V in the online-only 
Data Supplement), insufficient for a pathway analysis. 
Twelve of these 18 proteins changed both in the torce-
trapib plus atorvastatin and in the atorvastatin-only 
arm. Removing the 12 proteins shared by the 2 treat-
ment arms from the 200 proteins in the torcetrapib plus 
atorvastatin arm had little effect on the IPA top canoni-
cal pathway analysis results (Table VI in the online-only 
Data Supplement).
Protein Risk Scores at Baseline
At baseline, the 9-protein risk scores were similar 
among the 2 treatment arms (torcetrapib plus atorvas-
tatin, 7.7%; atorvastatin only, 7.2%; P=0.16). Among 
participants assigned to torcetrapib plus atorvastatin, 
the baseline 9-protein risk scores were 10.5% and 
6.5% for cases and controls, respectively (P=0.00046), 
and for participants assigned to atorvastatin only, the 
baseline risk scores were 8.44% and 6.0% for cases 
and controls, respectively (P=0.0066).
Changes in Protein Risk Scores With 
Treatment
Table  4 and Figure  4 show that from baseline to 3 
months, treatment with torcetrapib plus atorvastatin 
was associated with a within-participant increase in the 
absolute 9-protein risk score of 0.65% (P=0.0017) in all 
participants, 1.05% (P=0.006) in the cases, and 0.23% 
(P=0.10) in the controls. Compared across the 2 treat-
ment arms from baseline to 3 months, the 9-protein 
risk score increased in the torcetrapib plus atorvastatin 
arm compared with the atorvastatin-only arm in all 
participants by 1.08% (P=0.0004), in participants with 
events by 1.55% (P=0.004), and in participants with no 
events by 0.52% (P=0.039).
The changes in 9-protein risk with torcetrapib for 
the entire population of cases and controls showed a 
Figure 2. Proteins significantly altered by torcetrapib 
associated with aldosterone synthesis or function.  
Nodes represent gene symbol name, corresponding to 
protein measured. Degree of intensity of the node color (red) 
indicates degree of significance of the false discovery rate P 
value. Dashed lines correspond to the implicated function 
of the given proteins according to the Ingenuity Pathway 
Analysis knowledge bank. Node shapes denote cytokine 
(□), growth factor (⬚), and other (○). ANGPT2 indicates 
angiopoietin-2; BMP6, bone morphometric protein 6; DKK3, 
Dickkopf-related protein 3; NPPB, natriuretic peptide B; 
POMC, pro-opiomelanocortin; PYY, peptide YY; and TGFB1, 
transforming growth factor-β1. *Given protein was repre-
sented in the modified aptamer assay more than once.
Table 3. Proteins Significantly Altered by Torcetrapib 
Associated With Endocrine System Development and 
Function
Diseases or Functions 
Annotation Proteins P Value
Quantity of adiponectin Adiponectin, protein kinase 
B, GP4 CD36 platelet 
glycoprotein IV, growth 
hormone receptor
0.002
Synthesis of aldosterone Angiopoietin-2, bone 
morphogenetic protein-6, 
Dickkopf-related protein 3, 
β-endorphin
0.007
Insulin sensitivity Adiponectin, protein kinase B, 
apolipoprotein E, follistatin-
like 3, growth hormone 
receptor, glycogen synthase 
kinase-3 α, mitogen-activated 
protein kinase 8, protein 
kinase Cθ, tumor necrosis 
factor ligand superfamily 
member 12
0.016
Concentration of 
aldosterone
Angiopoietin-2, Dickkopf-
related protein 3, β-
endorphin, transforming 
growth factor-β1
0.018
Morphogenesis of islets of 
Langerhans
Matrix metalloproteinase-2, 
transforming growth factor-
β1
0.042
Release of aldosterone Brain natriuretic peptide 32, 
peptide YY
0.042
Release of hydrocortisone Brain natriuretic peptide 32, 
β-endorphin
0.042
Stimulation of aldosterone β-Endorphin, vasoactive 
intestinal peptide
0.042
Eight proteins are related to aldosterone synthesis or function. Nine proteins 
are related to insulin sensitivity and 2 proteins to pancreatic β-cell function 
(morphogenesis of islets of Langerhans).
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single distribution with no discontinuity (Ansari-Bradley 
test, P=0.15), suggesting that torcetrapib affected all 
exposed individuals to some extent (Figure XII in the 
online-only Data Supplement).
Changes in Framingham Risk Scores With 
Treatment
Framingham secondary event risk scores17 were bal-
anced across the 2 treatment arms at baseline (P=0.83). 
From baseline to 3 months, the Framingham risk score 
within participants decreased (mean [SD]) from 6.1% 
(2.5%) to 4.6% (2.0%) in the torcetrapib plus atorv-
astatin arm (P=2.2e−16) and remained unchanged 
from 6.1% (2.9%) to 6.2% (2.9%) in the atorvastatin 
alone arm (P=0.16). Cross-treatment comparison of the 
within-participant changes revealed a highly significant 
reduction in absolute Framingham risk favoring torce-
trapib plus atorvastatin over atorvastatin alone (−1.5%; 
P=2e−16).
Survey of Changes in Proteins 
Described Previously to Be Prognostic of 
Cardiovascular Events
We address here 200 proteins previously found to be 
prognostic of the same cardiovascular outcomes in a 
population of patients with coronary heart disease 
similar to that in the present study, measured by the 
same modified aptamer assay.8 In the present study, 
49 of those 200 prognostic proteins changed signifi-
cantly within the torcetrapib arm between baseline 
and 3 months (false discovery rate–corrected P<0.05; 
Table VII in the online-only Data Supplement). Among 
these proteins, 37 (76%) changed in the direction of 
increased risk and 12 proteins changed in the direction 
of reduced risk. Within the atorvastatin-only arm, only 
5 of the 200 prognostic proteins changed significantly 
(Table VII in the online-only Data Supplement).
DISCUSSION
In this retrospective proteomic analysis of the ILLUMI-
NATE trial,1 a survey of 1129 proteins at baseline and at 
3 months of treatment revealed heretofore unknown 
and widespread effects of torcetrapib on inflammation 
and immunity, with 8 of the top 10 canonical pathways 
affected by torcetrapib involved in inflammatory and 
immune functions. Pathway analysis also reinforced the 
previous finding of increased aldosterone levels with 
torcetrapib1 by pinpointing 8 plasma proteins altered by 
torcetrapib that relate to aldosterone synthesis or func-
tion. Pathway analysis also provided further explanation 
for the reported improvement in glycemic control with 
torcetrapib in the ILLUMINATE trial19,20 by identifying 9 
proteins related to insulin sensitivity and 2 proteins re-
lated to pancreatic β-cell function that are affected by 
torcetrapib. In addition, a previously validated 9-protein 
cardiovascular risk score8 predicted the harm associated 
with the use of torcetrapib at just 3 months of treat-
ment that had previously been observed by adverse car-
diovascular and mortality outcomes at 550 days (≈18 
months) of treatment when the study was halted.1 The 
results of this study suggest that a protein-based risk 
assessment embedded within a larger proteomic survey 
may prove to be useful in the clinical and mechanistic 
evaluation of therapies to prevent harm to patients.
The need for improved assessment of cardiovascular 
safety reached a turning point in 2004 to 2007 with 
a series of unfortunate events. First, rofecoxib (Vioxx), 
Table 4. Changes in Key Parameters From Baseline to 
3 Months in the 2 Treatment Arms
Parameter
Event 
Status
Torcetrapib 
Plus 
Atorvastatin
Change at 
3 mo
Atorvastatin 
Only Change 
at 3 mo
Treatment 
Difference
9-Protein risk 
score, %
Event 1.05† −0.50 1.55†
No event 0.23† −0.29 0.52*
Overall 0.65† −0.43 1.08†
HDL-C, mg/dL Event 24† 0 24†
No event 27† −1 28†
Overall 26† 0 26†
LDL-C, mg/dL Event −23† 2 −25†
No event −23† 1 −24†
Overall −23† 1.5 −24.5†
Systolic blood 
pressure, 
mm Hg
Event 0.25 1 −0.75
No event 4.5† −1.5 6.0†
Overall 3† −0.25 3.25†
Diastolic blood 
pressure, 
mm Hg
Event 1† 0 1
No event 2† −0.5 2.5†
Overall 1.5† 0 1.5†
Glucose, mg/
dL
Event 2 2 0
No event 0 5† −5*
Overall 0.5 4† −3.5*
eGFR mL/min 
per 1.73 m2
Event 2† 0 2
No event 0.75 0 0.75
Overall 1.33† 0 1.33*
Values are expressed as medians. Changes in risk scores represent the 
absolute risk score at 3 mo compared to the absolute risk score at baseline and 
the significance of the median change is determined compared to no change. 
Treatment difference is the difference between the change over 3 mo in 
absolute risk in the torcetrapib plus atorvastatin arm compared with the 
atorvastatin only arm. Protein risk score is calculated as the percent probability 
of an outcome event at 550 days.
eGFR indicates estimated glomerular filtration rate calculated with Chronic 
Kidney Disease Epidemiology Collaboration 201218; HDL-C, high-density 
lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol.
*P<0.05.
†P<0.01.
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a cyclooxygenase-2 inhibitor, was withdrawn from the 
market because of an adverse cardiovascular safety 
profile missed during its development.21,22 Then, the 
diabetes drug rosiglitazone (Avandia) was suspected 
of raising the risk of myocardial infarction, which also 
was not detected during its development.23 Finally, the 
ILLUMINATE trial results were even more concerning: 
There was a clear adverse effect of torcetrapib on car-
diovascular and all-cause mortality outcomes despite a 
remarkable improvement in lipid profile.1
The harmful effects of drugs could potentially be 
predicted early in clinical trials by the application of 
the modern tools of precision medicine. Measurement 
of proteins in particular is advantageous because they 
are the key regulators of biological processes in health 
and in diseases. Unlike genes, proteins can change over 
time to reflect alterations in disease risk. Although ge-
netic mendelian randomization approaches can also 
predict the effects of drugs on the intended pharmaco-
logical targets,24 only proteomic analyses can pinpoint 
any unsuspected drug toxicities that are related to off-
target effects of the drug molecule. Modified aptam-
ers have advanced the field of proteomics by enabling 
rapid quantification of hundreds or even thousands of 
proteins in a small volume of blood.8,10–13 The technique 
is highly sensitive, with a median limit of detection ≈1 
pg/mL, and precise, with median intra-assay and in-
terassay coefficients of variation <4%. The binding of 
modified aptamers to their intended protein target is 
highly specific and quantitative, as shown by the use of 
mass spectrometry as an orthogonal technique.12
The first objective in this study, enabled by a large-
scale proteomics survey, was to derive a mechanistic 
understanding of the biological effects of torcetrapib. 
The aim was to identify those proteins with levels that 
were significantly altered by torcetrapib and to organize 
any such differentially expressed proteins into biologi-
cal pathways.25 Unexpectedly, this process revealed that 
torcetrapib exerted biological effects that were wide-
spread, altering the plasma concentrations of 200 of the 
986 proteins (20.3%) successfully measured (Table II in 
the online-only Data Supplement). Furthermore, when 
organized according to biological pathways, this ap-
proach revealed that 8 of the top 10 canonical pathways 
affected by torcetrapib relate to inflammatory and im-
mune functions (Table II and Figures II–XI in the online-
only Data Supplement), effects not previously associated 
with torcetrapib. These results obtained through IPA were 
reinforced with Reactome (Table III in the online-only 
Data Supplement) and DAVID (Table IV in the online-only 
Data Supplement), which similarly revealed significant 
enrichment in pathways involving inflammation and im-
munity. This finding not only has important implications 
for increased cardiovascular risk observed with torcetra-
pib in the ILLUMINATE trial, because inflammation and 
immunity are central to cardiovascular disease,26 but 
also supports the possible contribution of the immune 
surveillance and inflammatory axes to the excess non-
cardiovascular deaths caused by sepsis and cancer with 
torcetrapib reported in the ILLUMINATE trial.1 Whether 
these inflammatory and immune function activities of 
torcetrapib are related specifically to the molecule itself 
or reflect accumulation of proinflammatory HDL particles 
from the inhibition of cholesterol ester transfer protein27 
can be resolved by proteomic investigation of trials that 
used other agents in the same class but with a different 
molecular structure. Some of the 200 proteins that were 
subjected to the IPA pathway analysis in the torcetrapib 
arm also changed in the atorvastatin-only arm. Excluding 
all 12 such proteins from the analysis did not materially 
alter our findings (Table VI in the online-only Data Sup-
plement). Because atorvastatin inhibits cholesterol ester 
transfer protein to raise HDL cholesterol,28 some of these 
shared proteins may relate to inhibition of the same cho-
Figure 3. Proteins significantly altered by torcetrapib 
associated with insulin sensitivity or pancreatic β-cell 
function.  
Nodes represent gene symbol name, corresponding to pro-
tein measured. Degree of intensity of the node color (red) in-
dicates degree of significance of false discovery rate P value. 
Dashed lines correspond to the implicated function of the 
given proteins according to the Ingenuity Pathway Analysis 
knowledge bank. Node shapes denote cytokine (□), growth 
factor (⬚), kinase (▽), peptidase ( ), transmembrane recep-
tor (⬯), transporter ( ), and other (○). ADIPO1 indicates 
adiponectin; C1Q, and collagen domain containing; APOE, 
apolipoprotein E, FSTL3, follistatin-like 3; GHR, growth 
hormone receptor; MAPK8, mitogen-activated protein ki-
nase-8; MMP2, matrix metalloproteinase-2; PRKCQ, protein 
kinase Cθ type; TGFB1, transforming growth factor-β1; and 
TNSFSF12, tumor necrosis factor superfamily member 12. 
*Given protein was represented in the modified aptamer 
assay more than once. 
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lesterol ester transfer protein target by torcetrapib and 
atorvastatin. Many proteins that we measured in plasma 
are secretable, evidenced by their gene encoding for a 
signal sequence or by meeting other established criteria 
for secretion.29 Other proteins we measured are typically 
considered intracellular; the mechanisms by which they 
appear in plasma remain largely speculative but include 
release by cell necrosis,30 cell apoptosis,30 reversible mem-
brane permeabilization,30 formation of cell membrane 
blebs,31 and extracellular vesicles.31
Our proteomic pathway analysis showed that torce-
trapib in ILLUMINATE also had major endocrine effects, 
particularly on aldosterone and glycemic control. Aldo-
sterone levels had been measured in a post hoc explor-
atory analysis to explain the observed elevations in blood 
pressure, reductions in potassium, and elevation in bi-
carbonate among patients who received torcetrapib.1 
At the time of the original publication, the mechanisms 
by which torcetrapib raised aldosterone levels were un-
known. In the present study, IPA identified significant en-
richment in 8 proteins involved in aldosterone synthesis, 
concentration, release, and stimulation (angiopoietin-2, 
bone morphogenetic protein 6, Dickkopf-related pro-
tein 3, β-endorphin/proopiomelanocortin, transforming 
growth factor-β1, natriuretic peptide [precursor] B, pep-
tide YY, and vasoactive intestinal peptide; Table 3 and 
Figure 2). Furthermore, the reduction in renin and the 
absence of an increase in adrenocorticotropic hormone 
observed in the present proteomic analysis are also con-
sistent with a direct action of torcetrapib leading to hy-
peraldosteronism. The ILLUMINATE trial also reported 
improved glycemic control with torcetrapib, explained 
predominantly by improved insulin sensitivity.19,20 No-
tably, pathway analysis identified 9 proteins related to 
insulin sensitivity and 2 proteins related to pancreatic β-
cell function altered by torcetrapib, providing potential 
mechanistic leads (Table 3 and Figure 3).
The second objective in the present study was to eval-
uate whether a previously validated 9-protein cardiovas-
cular risk score8 could detect the adverse effects of torce-
trapib at 3 months of treatment. The results show that 
this was achieved; despite differences in the study design 
and end points used in the present analysis compared 
with the larger ILLUMINATE trial, the absolute magnitude 
of the increase in risk of 1.08% predicted by the 9-pro-
tein risk score is consistent with the observed absolute 
1.2% increase in cardiovascular events with torcetra-
pib.1 This increased risk with torcetrapib likely affected 
all participants exposed because torcetrapib-associated 
changes in the 9-protein risk score represent a single 
statistical distribution (by the Ansari-Bradley test16). We 
used the 9-protein risk score to predict the response of 
torcetrapib because this risk score was mathematically 
derived from 1130 protein biomarkers that we previously 
tested; it is externally validated8 and applies to a popu-
lation of individuals with stable coronary heart disease 
similar to those in the ILLUMINATE study. We present the 
9-protein score as a proof of principle, acknowledging 
that other protein-based risk scores might perform well. 
Furthermore, 49 of the 200 proteins that were previously 
shown to be prognostic of cardiovascular and mortality 
outcomes in patients with coronary heart disease8 were 
Figure 4. Within-participant changes in 9-protein risk score, baseline to 3 months.  
A, Percent change in risk (3 months minus baseline) by treatment group. B, Percent change in risk (3 months minus baseline) 
by treatment group and event status. Legend to bar charts: Bar height extends to the median change in risk, and the whiskers 
represent the 95% confidence interval about the median. Labels at the top of each bar are the median risk change. P values 
on the sides of the bars are from testing with a Wilcoxon signed-rank test the null hypothesis that the risk change is distribut-
ed symmetrically with a median of zero. P values in brackets are from testing with a Wilcoxon rank-sum test the null hypoth-
esis of equal medians for the 2 populations. A indicates atorvastatin; and T, torcetrapib.
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affected by torcetrapib. The observation that 37 of 49 
prognostic proteins moved in the direction of adverse risk 
would create a significant concern for torcetrapib even in 
the absence of a formal 9-protein risk score. Twelve of 49 
prognostic proteins changed in the direction of reduced 
risk, suggesting that torcetrapib may have had some 
beneficial effects (perhaps mediated by LDL cholesterol 
reduction or improved glycemic control) but that these 
effects were masked by the dominant harmful effects 
of the drug. Although these 37 prognostic proteins in-
cluded 2 established cardiovascular biomarkers, notably 
troponin I (which is part of the 9-protein risk score) and 
brain (B-type) natriuretic peptide, C-reactive protein did 
not predict the harm from torcetrapib in this analysis. 
The observation that treatment-associated changes in 
C-reactive protein are strongly prognostic of the clini-
cal benefit derived from the cholesterol-lowering agents 
statins32–35 and ezetimibe36 but not prognostic of the 
harm from torcetrapib points to the advantages of a 
large-scale proteomic screen because individual biomark-
ers cannot be reasonably expected to cover all relevant 
biological systems and will inevitably miss some adverse 
drug effects. The up-front choice of which biomarkers 
would be affected is a guessing game that is rendered 
unnecessary by measuring them all (or as many as cur-
rent technology allows).
The hypertensive effects of torcetrapib were known 
early in its development,2 and one might reasonably 
question whether they should have raised greater con-
cern. However, a formal calculation of the Framingham 
secondary risk score in the present study shows con-
vincingly that the benefits of torcetrapib on steeply rais-
ing HDL cholesterol and lowering LDL cholesterol would 
be expected to outweigh the detriment in cardiovascu-
lar risk caused by the level of increased blood pressure 
observed. The improvement in Framingham risk score 
with torcetrapib clearly represents a false result and il-
lustrates how misleading risk calculation based on tra-
ditional risk factors would be in this instance, in con-
trast to the correct risk prediction based on the plasma 
proteome. The likely flaw in the Framingham risk calcu-
lation is that it focuses on HDL cholesterol levels with-
out accounting for HDL particle function.5
Limitations
The atorvastatin-only treatment arm had a slight, bor-
derline significant reduction in the 9-protein risk score 
at 3 months from baseline (0.43% absolute risk reduc-
tion, P=0.056), when perhaps no effect would have 
been expected. This is likely a “spillover” effect from 
the atorvastatin dose uptitration during the run-in 
phase of the study just before treatment randomiza-
tion.1 In this regard, it is known that higher doses of 
atorvastatin reduce cardiovascular risk more than lower 
doses.37 This potential spillover effect of atorvastatin 
uptitration would be expected to affect both treatment 
arms similarly.
Another potential limitation of the study is the 
nested case-control design of the present study. Avail-
able information strongly supports the use of nested 
case-control designs for the evaluation of risk predic-
tion measures in cardiovascular disease.14 Our statistical 
analyses focused primarily on group changes (ie, the 
increased risk we predicted approximated the risk ob-
served in the trial), and we did not examine how well 
our predictions may have performed in individual par-
ticipants (eg, by discrimination testing). Our results ap-
ply only to the population tested. It is not known how 
our findings would translate to cohorts with other char-
acteristics.
Last, some proteins are shared among ≥2 biological 
pathways. For the purposes of this study, we assumed 
that a change in a protein concentration affects all the 
pathways that contain it. The validity of that assump-
tion will be clarified by future studies.
Conclusions
The application of proteomics provides strong evidence 
and potential mechanistic explanations (through immu-
nity, inflammation, and endocrine effects) for harmful 
biological effects of torcetrapib that could have alerted 
investigators early in the ILLUMINATE trial or could have 
been useful when making the decision to proceed to 
this phase III study. Admittedly, the results of our study 
are novel and thus will need further validation. For ex-
ample, it would be interesting to compare these results 
with drugs of the same class that may not share mol-
ecule-specific off-target effects of torcetrapib such as 
Lilly’s evacetrapib, Roche’s dalcetrapib38 (both lacked ef-
ficacy in phase III trials but did not cause harm), or Mer-
ck’s anacetrapib. More broadly, our proteomic study 
provides evidence for the recent scientific statement 
from the American Heart Association that proteomics 
can have a “transformative impact for cardiovascular 
health and disease.”9
ARTICLE INFORMATION
Received March 4, 2017; accepted September 8, 2017.
The online-only Data Supplement is available with this article at http://circ.
ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.117.028213/-/
DC1.
Correspondence
Peter Ganz, MD, Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, 
Room 5G1, San Francisco, CA 94110. E-mail peter.ganz@ucsf.edu
Affiliations
SomaLogic, Inc., Boulder, CO (S.A.W., R.K.D., R.O., S.J.W.). Department of 
Medicine (A.C.M., P.G.) and Department of Epidemiology and Biostatistics 
(M.R.S.), University of California, San Francisco. Pfizer Inc., Worldwide Research 
Circulation. 2018;137:999–1010. DOI: 10.1161/CIRCULATIONAHA.117.028213 March 6, 2018 1009
Williams et al Assessment of Drug Safety Through Proteomics
ORIGINAL RESEARCH 
ARTICLE
and Development, Groton, CT (C.H.). Pfizer Inc., Worldwide Research and De-
velopment, Stockholm, Sweden (A.M.). Division of Cardiology, Zuckerberg San 
Francisco General Hospital, CA (P.G.).
Acknowledgments
The authors thank the Assay Execution Team at SomaLogic, Inc., for performing 
the SOMAscan assays; Christina Lee and Jennifer Hajj for providing logistical 
support; and Fraser Gaspar for statistical advice.
Sources of Funding 
The ILLUMINATE trial was supported by Pfizer Inc., and the proteomic analysis 
by SomaLogic, Inc. Dr Ganz’s proteomic research is supported by National Insti-
tutes of Health grants 1RO1HL129856, 1UO1DK108809, and 1R01AG052964.
Disclosures
Dr Murthy reports no conflict. Dr Ganz serves on a medical advisory board 
to SomaLogic, Inc., for which he accepts no salary, honoraria, or any other 
financial incentives. Drs DeLisle, Ostroff, Weiss, and Williams are employees of 
SomaLogic, Inc. Drs Hyde and Malarstig are employees of Pfizer Inc. Pfizer Inc. 
and SomaLogic, Inc., had a role in the design and conduct of the study; collec-
tion, management, analysis, and interpretation of the data; and preparation, 
review, and approval of the manuscript. Dr Ganz had the ultimate responsibility 
for all aspects of this study. Pfizer Inc. and SomaLogic, Inc., had no veto rights 
concerning the decision to submit the manuscript for publication.
REFERENCES
 1. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, 
Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr 
KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of 
torcetrapib in patients at high risk for coronary events. N Engl J Med. 
2007;357:2109–2122. doi: 10.1056/NEJMoa0706628.
 2. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the 
molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27:257–
260. doi: 10.1161/01.ATV.0000256728.60226.77.
 3. Berenson A. End of drug trial is a big loser for Pfizer. New York Times. 
2006. http://www.nytimes.com/2006/12/04/health/04pfizer.html. Ac-
cessed November 28, 2016.
 4. Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors: the 
clinical benefit of lipid drugs. N Engl J Med. 2015;373:1588–1591. doi: 
10.1056/NEJMp1508120.
 5. Vickers KC, Remaley AT. HDL and cholesterol: life after the divorce? J Lipid 
Res. 2014;55:4–12. doi: 10.1194/jlr.R035964.
 6. Robb MA, McInnes PM, Califf RM. Biomarkers and surrogate endpoints: 
developing common terminology and definitions. JAMA. 2016;315:1107–
1108. doi: 10.1001/jama.2016.2240.
 7. Brody E, Gold L, Mehan M, Ostroff R, Rohloff J, Walker J, Zichi D. Life’s 
simple measures: unlocking the proteome. J Mol Biol. 2012;422:595–606. 
doi: 10.1016/j.jmb.2012.06.021.
 8. Ganz P, Heidecker B, Hveem K, Jonasson C, Kato S, Segal MR, Sterling DG, 
Williams SA. Development and validation of a protein-based risk score 
for cardiovascular outcomes among patients with stable coronary heart 
disease. JAMA. 2016;315:2532–2541. doi: 10.1001/jama.2016.5951.
 9. Lindsey ML, Mayr M, Gomes AV, Delles C, Arrell DK, Murphy AM, Lange 
RA, Costello CE, Jin YF, Laskowitz DT, Sam F, Terzic A, Van Eyk J, Srini-
vas PR; American Heart Association Council on Functional Genomics and 
Translational Biology, Council on Cardiovascular Disease in the Young, 
Council on Clinical Cardiology, Council on Cardiovascular and Stroke 
Nursing, Council on Hypertension, and Stroke Council. Transformative im-
pact of proteomics on cardiovascular health and disease: a scientific state-
ment from the American Heart Association. Circulation. 2015;132:852–
872. doi: 10.1161/CIR.0000000000000226.
 10. Sabatine MS. Using aptamer-based technology to probe the plasma 
proteome for cardiovascular disease prediction. JAMA. 2016;315:2525–
2526. doi: 10.1001/jama.2016.6110.
 11. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J, Dalby AB, 
Eaton BE, Fitzwater T, Flather D, Forbes A, Foreman T, Fowler C, Gawande 
B, Goss M, Gunn M, Gupta S, Halladay D, Heil J, Heilig J, Hicke B, Husar 
G, Janjic N, Jarvis T, Jennings S, Katilius E, Keeney TR, Kim N, Koch TH, 
Kraemer S, Kroiss L, Le N, Levine D, Lindsey W, Lollo B, Mayfield W, Mehan 
M, Mehler R, Nelson SK, Nelson M, Nieuwlandt D, Nikrad M, Ochsner 
U, Ostroff RM, Otis M, Parker T, Pietrasiewicz S, Resnicow DI, Rohloff J, 
Sanders G, Sattin S, Schneider D, Singer B, Stanton M, Sterkel A, Stewart 
A, Stratford S, Vaught JD, Vrkljan M, Walker JJ, Watrobka M, Waugh S, 
Weiss A, Wilcox SK, Wolfson A, Wolk SK, Zhang C, Zichi D. Aptamer-
based multiplexed proteomic technology for biomarker discovery. PLoS 
One. 2010;5:e15004. doi: 10.1371/journal.pone.0015004.
 12. Ngo D, Sinha S, Shen D, Kuhn EW, Keyes MJ, Shi X, Benson MD, O’Sullivan 
JF, Keshishian H, Farrell LA, Fifer MA, Vasan RS, Sabatine MS, Larson MG, 
Carr SA, Wang TJ, Gerszten RE. Aptamer-based proteomic profiling reveals 
novel candidate biomarkers and pathways in cardiovascular disease. Circu-
lation. 2016;134:270–285. doi: 10.1161/CIRCULATIONAHA.116.021803.
 13. Gramolini A, Lau E, Liu PP. Identifying low-abundance biomarkers: ap-
tamer-based proteomics potentially enables more sensitive detection in 
cardiovascular diseases. Circulation. 2016;134:286–289. doi: 10.1161/
CIRCULATIONAHA.116.022940.
 14. Ganna A, Reilly M, de Faire U, Pedersen N, Magnusson P, Ingelsson E. 
Risk prediction measures for case-cohort and nested case-control designs: 
an application to cardiovascular disease. Am J Epidemiol. 2012;175:715–
724. doi: 10.1093/aje/kwr374.
 15. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quan-
titation. Clin Biochem Rev. 2008;29(suppl 1):S49–S52.
 16. Ansari AR, Bradley RA. Rank-sum tests for dispersions. Ann Math Statist. 
1960;31:1174–1189.
 17. D’Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson 
PW, Hartz SC. Primary and subsequent coronary risk appraisal: new results 
from the Framingham study. Am Heart J. 2000;139(pt 1):272–281.
 18. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, 
Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-
EPI Investigators. Estimating glomerular filtration rate from serum cre-
atinine and cystatin C. N Engl J Med. 2012;367:20–29. doi: 10.1056/
NEJMoa1114248.
 19. Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, 
Kastelein JJ. Effect of torcetrapib on glucose, insulin, and hemoglobin 
A1c in subjects in the Investigation of Lipid Level Management to Under-
stand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 
2011;124:555–562. doi: 10.1161/CIRCULATIONAHA.111.018259.
 20. Wiviott SD. ILLUMINATE sheds more light. Circulation. 2011;124:536–
537. doi: 10.1161/CIRCULATIONAHA.111.043323.
 21. Waxman HA. The lessons of Vioxx: drug safety and sales. N Engl J Med. 
2005;352:2576–2578. doi: 10.1056/NEJMp058136.
 22. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated 
with selective COX-2 inhibitors. JAMA. 2001;286:954–959.
 23. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocar-
dial infarction and death from cardiovascular causes. N Engl J Med. 
2007;356:2457–2471. doi: 10.1056/NEJMoa072761.
 24. Thanassoulis G, O’Donnell CJ. Mendelian randomization: nature’s ran-
domized trial in the post-genome era. JAMA. 2009;301:2386–2388. doi: 
10.1001/jama.2009.812.
 25. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: cur-
rent approaches and outstanding challenges. PLoS Comput Biol. 
2012;8:e1002375. doi: 10.1371/journal.pcbi.1002375.
 26. Libby P, Hansson GK. Inflammation and immunity in diseases of the arte-
rial tree: players and layers. Circ Res. 2015;116:307–311. doi: 10.1161/
CIRCRESAHA.116.301313.
 27. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. 
Arterioscler Thromb Vasc Biol. 2010;30:151–155. doi: 10.1161/ATVBA-
HA.108.179226.
 28. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer 
protein: at the heart of the action of lipid-modulating therapy with statins, 
fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart 
J. 2010;31:149–164. doi: 10.1093/eurheartj/ehp399.
 29. Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou 
A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Do-
berstein SK, Williams LT. Discovery of a cytokine and its receptor by func-
tional screening of the extracellular proteome. Science. 2008;320:807–
811. doi: 10.1126/science.1154370.
 30. Amgalan D, Pekson R, Kitsis RN. Troponin release following brief myo-
cardial ischemia: apoptosis versus necrosis. J Am Coll Cardiol Basic Trans 
Science. 2017;2:118–121.
 31. Hickman PE, Potter JM, Aroney C, Koerbin G, Southcott E, Wu AH, Roberts 
MS. Cardiac troponin may be released by ischemia alone, without necro-
sis. Clin Chim Acta. 2010;411:318–323. doi: 10.1016/j.cca.2009.12.009.
March 6, 2018 Circulation. 2018;137:999–1010. DOI: 10.1161/CIRCULATIONAHA.117.0282131010
Williams et al Assessment of Drug Safety Through Proteomics
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
 32. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein 
JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, 
Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Reduction in 
C-reactive protein and LDL cholesterol and cardiovascular event rates after 
initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 
2009;373:1175–1182. doi: 10.1016/S0140-6736(09)60447-5.
 33. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui 
A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive pro-
tein during follow-up of patients with acute coronary syndromes in the 
Aggrastat-to-Zocor Trial. Circulation. 2006;114:281–288. doi: 10.1161/
CIRCULATIONAHA.106.628909.
 34. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem 
J, Magorien RD, O’Shaughnessy C, Ganz P; Reversal of Atherosclerosis 
with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, 
LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J 
Med. 2005;352:29–38. doi: 10.1056/NEJMoa042000.
 35. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfef-
fer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection 
Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) In-
vestigators. C-reactive protein levels and outcomes after statin therapy. N 
Engl J Med. 2005;352:20–28. doi: 10.1056/NEJMoa042378.
 36. Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Ter-
shakovec AM, Blazing MA, Braunwald E. Achievement of dual low-density 
lipoprotein cholesterol and high-sensitivity C-reactive protein targets more 
frequent with the addition of ezetimibe to simvastatin and associated 
with better outcomes in IMPROVE-IT. Circulation. 2015;132:1224–1233. 
doi: 10.1161/CIRCULATIONAHA.115.018381.
 37. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto 
AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New 
Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in pa-
tients with stable coronary disease. N Engl J Med. 2005;352:1425–1435. 
doi: 10.1056/NEJMoa050461.
 38. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, 
Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray 
JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES 
Investigators. Effects of dalcetrapib in patients with a recent acute coro-
nary syndrome. N Engl J Med. 2012;367:2089–2099. doi: 10.1056/ 
NEJMoa1206797.
Kuang-Tien General Hospital (Taichug, Taiwan)
Kuang Tien General Hospital was founded in 1913 by Dr Tong Chong Wang. At the time, its name was Yang Zhen Hospital, and 
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Yu Ling Wang, PhD, and Dr Nai Phon Wang, PhD, Kuang Tien General Hospital has become the longest running sole proprietorship 
hospital in Taiwan, with over 1300 beds and nearly 2000 employees. Kuang Tien's affiliated organizations include: Hung Kuang 
University, Hung Kuang University Affiliated Aging Care Hospital, Ching Chuan Hospital, and Tong Siao Hospital (lower right).
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Throat Center, Cancer Center, and Cardiovascular Care Center. In line with its longstanding dedication to comprehensive care, 
in 2006, Kuang Tien extended its services from preventive care and acute care to chronic care with the establishment of the 
long-term care facility, Chang Ching Branch, which includes a nursing home, day care center, and dementia care center.
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